Low Grade Glioma

NCI Definition: A grade I or grade II glioma arising from the central nervous system. This category includes pilocytic astrocytoma, diffuse astrocytoma, subependymal giant cell astrocytoma, ependymoma, oligodendroglioma, oligoastrocytoma, and angiocentric glioma. [1]

Low grade gliomas most frequently harbor alterations in IDH1, CIC, BRAF, TP53, and NOTCH1 [2].

Most Commonly Altered Genes in Low Grade Glioma

IDH1 Mutation, IDH1 Codon 132 Missense, IDH1 R132H, TP53 Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in low grade glioma [2].

Top Alterations in Low Grade Glioma

Clinical Trials

View Clinical Trials for Low Grade Glioma

There are 18 clinical trials for low grade glioma, of which 18 are open and 0 are completed or closed. Of the trials that contain low grade glioma as an inclusion criterion, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (4 open), 5 are phase 2 (5 open), and 3 are phase 3 (3 open).

BRAF, NF1, and ARAF are the most frequent gene inclusion criteria for low grade glioma clinical trials [3].

Trials Investigating Low Grade Glioma by Gene and Recruiting Status

Vincristine, day101, and carboplatin are the most common interventions in low grade glioma clinical trials.

Drugs Being Investigated in Low Grade Glioma Trials by Recruiting Status

Significant Genes in Low Grade Glioma

ARAF +

ARAF is altered in 0.9% of low grade glioma patients [2].

ARAF is an inclusion eligibility criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain ARAF status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

BRAF +

BRAF is altered in 15.26% of low grade glioma patients [2].

BRAF is an inclusion eligibility criterion in 6 clinical trials for low grade glioma, of which 6 are open and 0 are closed. Of the trials that contain BRAF status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [3].

CRKL +

CRKL is altered in 0.23% of low grade glioma patients [2].

CRKL is an inclusion eligibility criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

EGFR +

EGFR is altered in 2.82% of low grade glioma patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERBB2 +

ERBB2 is altered in 0.94% of low grade glioma patients [2].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FGFR1 +

FGFR1 is altered in 4.08% of low grade glioma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR2 +

FGFR2 is altered in 1.15% of low grade glioma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR3 +

FGFR3 is altered in 1.98% of low grade glioma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HRAS +

HRAS is altered in 0.52% of low grade glioma patients [2].

HRAS is an inclusion eligibility criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

IDH1 +

IDH1 is altered in 49.63% of low grade glioma patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and low grade glioma as inclusion criteria, 1 is phase 3 (1 open) [3].

IDH2 +

IDH2 is altered in 6.98% of low grade glioma patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and low grade glioma as inclusion criteria, 1 is phase 3 (1 open) [3].

KIAA1549 +

KIAA1549 is altered in 10.4% of low grade glioma patients [2].

KIAA1549 is an inclusion eligibility criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains KIAA1549 status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KRAS +

KRAS is altered in 3.45% of low grade glioma patients [2].

KRAS is an inclusion eligibility criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MAP2K1 +

MAP2K1 is altered in 0.78% of low grade glioma patients [2].

MAP2K1 is an inclusion eligibility criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 +

MAP2K2 is altered in 0.7% of low grade glioma patients [2].

MAP2K2 is an inclusion eligibility criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K2 status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 +

MAP2K4 is altered in 0.67% of low grade glioma patients [2].

MAP2K4 is an inclusion eligibility criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K4 status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 +

MAP3K1 is altered in 2.57% of low grade glioma patients [2].

MAP3K1 is an inclusion eligibility criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP3K1 status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MAPK1 +

MAPK1 is altered in 0.36% of low grade glioma patients [2].

MAPK1 is an inclusion eligibility criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain MAPK1 status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MYB +

MYB is altered in 1.11% of low grade glioma patients [2].

MYB is an inclusion eligibility criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains MYB status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYBL1 +

MYBL1 is altered in 1.98% of low grade glioma patients [2].

MYBL1 is an inclusion eligibility criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains MYBL1 status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF1 +

NF1 is altered in 8.15% of low grade glioma patients [2].

NF1 is an inclusion eligibility criterion in 5 clinical trials for low grade glioma, of which 5 are open and 0 are closed. Of the trials that contain NF1 status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [3].

NF2 +

NF2 is altered in 1.58% of low grade glioma patients [2].

NF2 is an inclusion eligibility criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS +

NRAS is altered in 0.94% of low grade glioma patients [2].

NRAS is an inclusion eligibility criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

PTPN1 +

PTPN1 is an inclusion eligibility criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains PTPN1 status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAF1 +

RAF1 is altered in 1.02% of low grade glioma patients [2].

RAF1 is an inclusion eligibility criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain RAF1 status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

SOS1 +

SOS1 is altered in 0.94% of low grade glioma patients [2].

SOS1 is an inclusion eligibility criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SRC +

SRC is altered in 0.62% of low grade glioma patients [2].

SRC is an inclusion eligibility criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain SRC status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

Disease Details

Synonyms

Low-Grade Glioma, Circumscribed low grade glioma

Parent(s)

Glioma

Children

Angiocentric Glioma, Pleomorphic Xanthoastrocytoma, Low Grade Astrocytic Tumor, WHO Grade II Glioma, Ganglioglioma, and Low-Grade Glioma, NOS

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Low Grade Glioma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Low Grade Glioma

Disease Details

References

About

Molecular Medicine

Content Types